Since TIB prevented the killing of the luminal BCC line MCF7, we questioned whether TIB would have a similar effect on the more aggressive Claudin-low type MDA-MB-231 (ER-, PR-, Her2-) triple-negative BCCs. The gene discussed is ESR1; the disease is skin basal cell carcinoma.